trending Market Intelligence /marketintelligence/en/news-insights/trending/VkeI0znUZ0vD8UkYq0ZWtw2 content esgSubNav
In This List

Catalent negotiates decrease in term loan interest rate

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Catalent negotiates decrease in term loan interest rate

Catalent Pharma Solutions Inc. negotiated a decrease in the interest rates of its U.S. dollar-denominated and euro-denominated term loans.

The Catalent Inc. subsidiary will pay 2.75% plus LIBOR on its U.S. dollar-denominated loan, down 0.50% on the previous rate, and 2.50% plus LIBOR on euro-denominated loan, 0.75% lower than the prior rate.

Catalent Inc. had $1.45 billion outstanding under its U.S. dollar-denominated term loan facility as of Sept. 30; it had $350.5 million outstanding under its euro-denominated facility on the same date.